A small drug discovery outfit is challenging one of the world’s largest drugmakers in a cancer drug patent dispute.
Over the past 10 years, we’ve covered scores of deals—and rumors of deals—and now, we're asking you to choose the best and worst of them.
Especially after the week Teva’s had, it may need to pay up—big time—to land a CEO that can help it turn its fortunes.
FiercePharma kept track as the industry launched drugs, made deals, lost patents, shrank, grew, innovated and revolutionized since 2007. Here's how.
Martin Shkreli, who became notorious for jacking up the price of a drug by 5,000%, has been convicted in New York of federal securities fraud.
Jazz won an FDA nod Thursday for its Vyxeo combination-chemo treatment, part of the company's bid to diversify ahead of Xyrem generics.
With billions in sales under threat, AbbVie is going all out in defense of its key drug and the world’s best seller, Humira.
During a tough 2016, only three large drugmakers added jobs and five cut them. AbbVie's roster grew the most, followed by Roche and Lilly.
Valneva and Emergent BioSolutions will co-develop a Zika candidate slated to enter phase 1 in late 2017 or early 2018.
Bristol-Myers Squibb and Clovis Oncology plan to pair two of their oncology drugs in several cancer types.